nach oben

Erschienen in:

01.05.2015 | Research Article

Knockdown of Aurora-B alters osteosarcoma cell malignant phenotype via decreasing phosphorylation of VCP and NF-κB signaling

verfasst von: Jian Ying He, Wei Hong Xi, Liang Bo Zhu, Xin Hua Long, Xuan Yin Chen, Jia Min Liu, Qin Feng Luo, Xiao Ping Zhu, Zhi Li Liu

Erschienen in: Tumor Biology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to investigate the effects of inhibiting Aurora-B on osteosarcoma (OS) cell malignant phenotype, phosphorylation of valosin-containing protein (VCP), and the activity of NF-κB signaling in vitro. The expressions of Aurora-B and p-VCP proteins were detected by immunohistochemistry in 24 OS tissues, and the relationship between Aurora-B and p-VCP was investigated. The results showed that there was a positive correlation between Aurora-B and p-VCP proteins. The expression of Aurora-B in human OS cell lines U2-OS and HOS cells was inhibited by specific short hairpin RNA (shRNA) lentivirus (AURKB-shRNA lentivirus, Lv-shAURKB) which targeted Aurora-B. The results showed that the phosphorylation of VCP, the activity of NF-κB signaling pathway and the malignant phenotype of OS cells were all suppressed by knockdown of Aurora-B. It indicated that the inhibition of Aurora-B alters OS cells malignant phenotype by downregulating phosphorylation of VCP and activating of the NF-κB signaling pathway in vitro.

Nur mit Berechtigung zugänglich

Mialou V, Philip T, Kalifa C, Perol D, Gentet JC, Marec-Berard P, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome—the French pediatric experience. Cancer. 2005;104(5):1100–9. doi:10.1002/cncr.21263.CrossRefPubMed

Hegyi M, Semsei AF, Jakab Z, Antal I, Kiss J, Szendroi M, et al. Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. Pediatr Blood Cancer. 2011;57(3):415–22. doi:10.1002/pbc.23172.CrossRefPubMed

Stokkel MP, Linthorst MF, Borm JJ, Taminiau AH, Pauwels EK. A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma. J Cancer Res Clin Oncol. 2002;128(7):393–9. doi:10.1007/s00432-002-0350-5.CrossRefPubMed

Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, et al. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J Biol Chem. 2012;287(35):29887–98. doi:10.1074/jbc.M112.371682.CrossRefPubMedPubMedCentral

Tsuno T, Natsume A, Katsumata S, Mizuno M, Fujita M, Osawa H, et al. Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells. J Neurooncol. 2007;83(3):249–58. doi:10.1007/s11060-007-9335-1.CrossRefPubMed

Pohl A, Azuma M, Zhang W, Yang D, Ning Y, Winder T, et al. Pharmacogenetic profiling of Aurora kinase B is associated with overall survival in metastatic colorectal cancer. Pharmacogenomics J. 2011;11(2):93–9. doi:10.1038/tpj.2010.18.CrossRefPubMed

Hetland TE, Nymoen DA, Holth A, Brusegard K, Florenes VA, Kaern J, et al. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. Hum Pathol. 2013;44(5):777–85. doi:10.1016/j.humpath.2012.08.002.CrossRefPubMed

Sanchez-Bailon MP, Calcabrini A, Gomez-Dominguez D, Morte B, Martin-Forero E, Gomez-Lopez G, et al. Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells. Cell Signal. 2012;24(6):1276–86.CrossRefPubMed

Li WW, Long GX, Liu DB, Mei Q, Wang JF, Hu GY, et al. Cyclooxygenase-2 inhibitor celecoxib suppresses invasion and migration of nasopharyngeal carcinoma cell lines through a decrease in matrix metalloproteinase-2 and -9 activity. Pharmazie. 2014;69(2):132–7.PubMed

10.

Roomi MW, Kalinovsky T, Rath M, Niedzwiecki A. In vitro modulation of MMP-2 and MMP-9 in pediatric human sarcoma cell lines by cytokines, inducers and inhibitors. Int J Oncol. 2014;44(1):27–34. doi:10.3892/ijo.2013.2159.PubMed

11.

Liao CL, Lin JH, Lien JC, Hsu SC, Chueh FS, Yu CC, et al. The crude extract of Corni fructus inhibits the migration and invasion of U-2 OS human osteosarcoma cells through the inhibition of matrix metalloproteinase-2/-9 by MAPK signaling. Environ Toxicol. 2013. doi:10.1002/tox.21894.

12.

Tomonaga M, Hashimoto N, Tokunaga F, Onishi M, Myoui A, Yoshikawa H, et al. Activation of nuclear factor-kappa B by linear ubiquitin chain assembly complex contributes to lung metastasis of osteosarcoma cells. Int J Oncol. 2012;40(2):409–17. doi:10.3892/ijo.2011.1209.PubMed

13.

Vandermoere F, El Yazidi-Belkoura I, Slomianny C, Demont Y, Bidaux G, Adriaenssens E, et al. The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival. J Biol Chem. 2006;281(20):14307–13. doi:10.1074/jbc.M510003200.CrossRefPubMed

14.

Long XH, Zhang ZH, Liu ZL, Huang SH, Luo QF. Inhibiting valosin-containing protein suppresses osteosarcoma cell metastasis via AKT/nuclear factor of kappa B signaling pathway in vitro. Indian J Pathol Microbiol. 2013;56(3):190–5. doi:10.4103/0377-4929.120358.CrossRefPubMed

15.

Dobrynin G, Popp O, Romer T, Bremer S, Schmitz MH, Gerlich DW, et al. Cdc48/p97-Ufd1-Npl4 antagonizes Aurora B during chromosome segregation in HeLa cells. J Cell Sci. 2011;124(Pt 9):1571–80. doi:10.1242/jcs.069500.CrossRefPubMed

16.

Ioannou M, Kouvaras E, Stathakis E, Samara M, Koukoulis GK. Aurora B kinase in Hodgkin lymphoma: immunohistochemical pattern of expression in neoplastic Hodgkin and Reed-Sternberg cells. J Mol Histol. 2013. doi:10.1007/s10735-013-9561-0.PubMed

17.

Long ZJ, Xu J, Yan M, Zhang JG, Guan Z, Xu DZ, et al. ZM 447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three-dimensional culture. Cell Cycle. 2008;7(10):1473–9.CrossRefPubMed

18.

Mehra R, Serebriiskii IG, Burtness B, Astsaturov I, Golemis EA. Aurora kinases in head and neck cancer. Lancet Oncol. 2013;14(10):e425–35. doi:10.1016/S1470-2045(13)70128-1.CrossRefPubMedPubMedCentral

19.

Jha HC, Lu J, Saha A, Cai Q, Banerjee S, Prasad MA, et al. EBNA3C-mediated regulation of aurora kinase B contributes to Epstein-Barr virus-induced B-cell proliferation through modulation of the activities of the retinoblastoma protein and apoptotic caspases. J Virol. 2013;87(22):12121–38. doi:10.1128/JVI. 02379-13.CrossRefPubMedPubMedCentral

20.

Marampon F, Gravina GL, Popov VM, Scarsella L, Festuccia C, La Verghetta ME, et al. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. Int J Oncol. 2014;44(1):285–94. doi:10.3892/ijo.2013.2167.PubMed

21.

Wang Q, Song C, Li CC. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. J Struct Biol. 2004;146(1–2):44–57. doi:10.1016/j.jsb.2003.11.014.CrossRefPubMed

22.

Rumpf S, Lee SB, Jan LY, Jan YN. Neuronal remodeling and apoptosis require VCP-dependent degradation of the apoptosis inhibitor DIAP1. Development. 2011;138(6):1153–60. doi:10.1242/dev.062703.CrossRefPubMedPubMedCentral

23.

Hotta K, Nashimoto A, Yasumura E, Suzuki M, Azuma M, Iizumi Y, et al. Vesnarinone suppresses TNFalpha mRNA expression by inhibiting valosin-containing protein. Mol Pharmacol. 2013;83(5):930–8. doi:10.1124/mol.112.081935.CrossRefPubMed

24.

Andela VB, Gordon AH, Zotalis G, Rosier RN, Goater JJ, Lewis GD, et al. NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res. 2003;415 Suppl:S75–85. doi:10.1097/01.blo.0000093048.96273.aa.

25.

Felx M, Guyot MC, Isler M, Turcotte RE, Doyon J, Khatib AM, et al. Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappaB in human osteosarcoma. Clin Sci (Lond). 2006;110(6):645–54. doi:10.1042/CS20050286.CrossRef

Titel: Knockdown of Aurora-B alters osteosarcoma cell malignant phenotype via decreasing phosphorylation of VCP and NF-κB signaling
verfasst von: Jian Ying He
Wei Hong Xi
Liang Bo Zhu
Xin Hua Long
Xuan Yin Chen
Jia Min Liu
Qin Feng Luo
Xiao Ping Zhu
Zhi Li Liu
Publikationsdatum: 01.05.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 5/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-3032-4

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Knockdown of Aurora-B alters osteosarcoma cell malignant phenotype via decreasing phosphorylation of VCP and NF-κB signaling

Abstract

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications

HOXA5 indicates poor prognosis and suppresses cell proliferation by regulating p21 expression in non small cell lung cancer

Involvement of NEDD9 in the invasion and migration of gastric cancer

Long noncoding RNA MALAT1 associates with the malignant status and poor prognosis in glioma

The 7th AJCC/UICC TNM staging system may be not suitable in predicting prognosis of synchronous multiple gastric carcinoma patients with D2 gastrectomy

Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis

Neu im Fachgebiet Onkologie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

Update Onkologie